المؤلفون: L. A. Suplotova, L. V. Kaplina, T. S. Dushina, O. B. Makarova, Л. А. Суплотова, Л. В. Каплина, Т. С. Душина, О. Б. Макарова

المصدر: Meditsinskiy sovet = Medical Council; № 23 (2023); 234-242 ; Медицинский Совет; № 23 (2023); 234-242 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: инсулинорезистентность, non-alcoholic fatty disease, non-alcoholic steatohepatitis, fibrosis, type 2 diabetes mellitus, insulin resistance, неалкогольная жировая болезнь, неалкогольный стеатогепатит, фиброз, сахарный диабет 2-го типа

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/8023/7115Test; Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. https://doi.org/10.1002/hep.28431Test.; Ивашкин ВТ, Драпкина ОМ, Маев ИВ, Трухманов АС, Блинов ДВ, Пальгова ЛК и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2015;25(6):31–41. https://doi.org/10.12691/ajcmr-3-2-3Test.; Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792–798. https://doi.org/10.1002/hep.22429Test.; Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int. 2010;30(6):795–808. https://doi.org/10.1111/j.1478-3231.2010.02264.xTest.; Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Nonalcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med. 2005;22(10):1354–1358. https://doi.org/10.1111/j.1464-5491.2005.01646.xTest.; Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009;9(3):299–314. https://doi.org/10.2174/156652409787847191Test.; Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut. 2010;59(2):267–273. https://doi.org/10.1136/gut.2009.190801Test.; Yamanouchi T. Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes. Vasc Health Risk Manag. 2010;6:189–197. https://doi.org/10.2147/vhrm.s5838Test.; Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011;2(4):236–240. https://doi.org/10.4103/22314040.90879Test.; Дедов ИИ. Сахарный диабет: развитие технологий в диагностике, лечении и профилактике (пленарная лекция). Сахарный диабет. 2010;(3):6–13. Режим доступа: https://www.elibrary.ru/download/elibrary_15600463_13067605.pdfTest.; Yki-Jarvinen H. Thiazolidinediones. New Engl J Med. 2004;351(11):1106–1118. https://doi.org/10.1056/NEJMra041001Test.; Sohda T, Mizuno K, Imamiya E, Sugiyama Y, Fujita T., Kawamatsu Y. Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl] thiazolidine-2,4-dione (ADD-3878) and its derivatives. Chem Pharm Bull (Tokyo). 1982;30(10):3580–3600. https://doi.org/10.1248/Cpb.30.3580Test.; Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes. 1983;32(9):804–810. https://doi.org/10.2337/diab.32.9.804Test.; Yang K, Woodhead JL, Watkins PB, Howell BA, Brouwer KLR. Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin Pharmacol Ther. 2014;96(5):589–598. https://doi.org/10.1038/clpt.2014.158Test.; Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25(5):815–821. https://doi.org/10.2337/diacare.25.5.81Test.; Bolton GC, Keogh JP, East PD, Hollis FJ, Shore FD. The fate of a thiazolidinedione antidiabetic agent in rat and dog. Xenobiotica. 1996;26(6):627–636. https://doi.org/10.3109/00498259609046738Test.; Shibata H, Nii S, Kobayashi M, Izumi T, Maeda E. Phase I study of a new hypoglycemic agent CS 045 in healthy volunteers: safety and pharmacokinetics in single administration. Rinsho Riinsho Iyaku. 1993;9:1503–1518. Available at: https://www.researchgate.net/publication/286392580_Phase_I_study_of_a_new_hypoglycemic_agent_CS-045_in_healthy_volunteers_Safety_and_pharmacokinetics_in_single_administrationTest.; Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998;284:751–759. Available at: https://pubmed.ncbi.nlm.nih.gov/9454824Test.; Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471. https://doi.org/10.1056/NEJMoa072761Test.; Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373(9681):2125–2135. https://doi.org/10.1016/s0140-6736Test(09)60953-3.; Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294(20):2581–2586. https://doi.org/10.1001/jama.294.20.joc50147Test.; Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspectivepioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289. https://doi.org/110.1016/S01406736Test(05)67528-9.; Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D’Agostino Sr RB et al. Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thicknes in Type 2 Diabetes: A Randomized Trial. JAMA. 2006;296(21):2572–2581. https://doi.org/110.1001/jama.296.21.joc60158Test.; Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–1573. https://doi.org/110.1001/jama.299.13.1561Test.; Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf. 2007;16(10):1065–1071. https://doi.org/10.1002/pds.1470Test.; Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf. 2009;32(9):787–800. https://doi.org/10.2165/11316510-000000000-00000Test.; Kawamori R, Kadowaki T, Onjic M, Seino Y, Akanuma Y. Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in Japan. Diabetes Res Clin Pract. 2007;76(2):229–35. https://doi.org/10.1016/j.diabres.2006.08.017Test.; Ahmad SR. Adverse drug monitoring at the Food and Drug Administration. J Gen Intern Med. 2003;18(1):57–60. https://doi.org/10.1046/j.1525-1497.2003.20130.xTest.; Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528–562. https://doi.org/10.1016/j.eprac.2022.03.010Test.; European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. https://doi.org/10.1016/j.jhep.2015.11.004Test.; Голованова ЕВ, Туркина СВ, Райхельсон КЛ, Оковитый СВ, Драпкина ОМ, Маев ИВ и др. Неалкогольная жировая болезнь печени у взрослых: клинические рекомендации. 2022. Режим доступа: https://diseases.medelement.comTest/disease/неалкогольная-жировая-болезнь-печени-у-взрослых-кпрф-2022/17468.; Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362(18):1675–1685. https://doi.org/10.1056/NEJMoa0907929Test.; Della Pepa G, Russo M, Vitale M, Carli F, Vetrani C, Masulli M et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res Clin Pract. 2021;178:108984. https://doi.org/10.1016/j.diabres.2021.108984Test.; Zhao Y, Zhao W, Wang H, Zhao Y, Bu H, Takahashi H. Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs. Medicine (Baltimore). 2022;101(46):e31508. https://doi.org/10.1097/MD.0000000000031508Test.; Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology. 2015;62(5):1417–1432. https://doi.org/10.1002/hep.27999Test.; He L, Liu X, Wang L, Yang Z. Thiazolidinediones for Nonalcoholic Steatohepatitis: A Meta-Analysis of Randomized Clinical Trials. Med (Baltimore). 2016;95(42):e4947. https://doi.org/10.1097/md.0000000000004947Test.; Glen J, Floros L, Day C, Pryke R. Non-Alcoholic Fatty Liver Disease (NAFLD): Summary of NICE Guidance. BMJ. 2016;354:i4428. https://doi.org/10.1136/bmj.i4428Test.; Bril F, Kalavalapalli S, Clark VC, Lomonaco RS. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clin Gastroenterol Hepatol. 2018;16(4):558–566. https://doi.org/10.1016/j.cgh.2017.12.001Test.; Boettcher E, Csako G, Pucino F, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35(1):66–75. https://doi.org/10.1111/j.1365-2036.2011.04912.xTest.; Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting. Diabetes Care. 2011;34(6):1369–1371. https://doi.org/10.2337/dc10-2412Test.; Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297–2307. https://doi.org/10.1056/NEJMoa060326Test.; Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis – a systematic review and meta-analysis. J. Hepatol. 2011;55(6):1383–1390. https://doi.org/10.1016/j.jhep.2011.03.016Test.; Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017;177(5):633–640. https://doi.org/10.1001/jamainternmed.2016.9607Test.; https://www.med-sovet.pro/jour/article/view/8023Test

الإتاحة: https://doi.org/10.21518/ms2023-462Test
https://doi.org/10.1002/hep.28431Test
https://doi.org/10.12691/ajcmr-3-2-3Test
https://doi.org/10.1002/hep.22429Test
https://doi.org/10.1111/j.1478-3231.2010.02264.xTest
https://doi.org/10.1111/j.1464-5491.2005.01646.xTest
https://doi.org/10.2174/156652409787847191Test
https://doi.org/10.1136/gut.2009.190801Test
https://doi.org/10.2147/vhrm.s5838Test
https://doi.org/10.4103/22314040.90879Test

مصطلحات موضوعية: панкреостеатонекроз, experimental model, поджелудочная железа, non-alcoholic fatty disease of the pancreas, неалкогольная жировая болезнь поджелудочной железы, pancreas, pancreatic osteonecrosis, экспериментальная модель

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::e29fccf0ac2a69697db515bd767a81b8Test

المؤلفون: Олег Якович Бабак

المصدر: ScienceRise, Vol 4, Iss 3 (21), Pp 27-32 (2016)

مصطلحات موضوعية: factor of fibroblasts-21 growth, non-alcoholic fatty disease of liver, hypertonic disease, overweight, obesity, Science (General), Q1-390

العلاقة: http://journals.uran.ua/sciencerise/article/view/67683Test; https://doaj.org/toc/2313-6286Test; https://doaj.org/toc/2313-8416Test; https://doaj.org/article/e7e99dfe2acc4445b9f12f4c256b7b4aTest

الإتاحة: https://doi.org/10.15587/2313-8416.2016.67683Test
https://doaj.org/article/e7e99dfe2acc4445b9f12f4c256b7b4aTest

المؤلفون: M M Severova, E A Saginova, M G Gallyamov, N V Ermakov, A V Rodina, V V Fomin, N A Mukhin

المصدر: Терапевтический архив, Vol 84, Iss 6, Pp 15-20 (2012)

مصطلحات موضوعية: non-alcoholic fatty disease of the liver, metabolic syndrome, cardiorenal syndrome, leptin, adiponectin, insulin resistance, Medicine

وصف الملف: electronic resource

العلاقة: https://ter-arkhiv.ru/0040-3660/article/view/31029Test; https://doaj.org/toc/0040-3660Test; https://doaj.org/toc/2309-5342Test

الوصول الحر: https://doaj.org/article/4bcdae9fc3964343a3d95062df9cd772Test

المصدر: ScienceRise; Том 4, № 3 (21) (2016); 27-32

مصطلحات موضوعية: УДК: 616.36-003.826:616.12-008.331.1-078:57.083.3, фактор росту фібробластів-21, неалкогольна жирова хвороба печінки, гіпертонічна хвороба, надлишкова вага тіла, ожиріння, factor of fibroblasts-21 growth, non-alcoholic fatty disease of liver, hypertonic disease, overweight, obesity

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=scientific_p::c1fe68d82f22294c52430ec9310791caTest
http://journals.uran.ua/sciencerise/article/view/67683Test

المصدر: ScienceRise, Vol 4, Iss 3 (21), Pp 27-32 (2016)

مصطلحات موضوعية: factor of fibroblasts-21 growth, Anamnesis, obesity, medicine.medical_specialty, FGF21, business.industry, General Medicine, Urine, Overweight, medicine.disease, Gastroenterology, Obesity, hypertonic disease, Endocrinology, Internal medicine, Blood plasma, overweight, Medicine, medicine.symptom, Risk factor, lcsh:Science (General), business, non-alcoholic fatty disease of liver, Body mass index, lcsh:Q1-390

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a638ad6d02fd871a1cb241b972ae55f3Test
https://doi.org/10.15587/2313-8416.2016.67683Test

المؤلفون: Mariya Severova, Saginova, E. A., Gallyamov, M. G., Ermakov, N. V., Rodind, A. V., Fomin, V. V., Mukhin, N. A.

المصدر: Scopus-Elsevier
Терапевтический архив, Vol 84, Iss 6, Pp 15-20 (2012)

مصطلحات موضوعية: cardiorenal syndrome, adiponectin, insulin resistance, lcsh:R, cardiovascular system, non-alcoholic fatty disease of the liver, lcsh:Medicine, cardiovascular diseases, leptin, metabolic syndrome

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::7c8b4330869a0d1c22d10475d1644efdTest
http://www.scopus.com/inward/record.url?eid=2-s2.0-84867650500&partnerID=MN8TOARSTest